SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: dorightbythem1/20/2019 10:44:08 PM
2 Recommendations

Recommended By
bnutman
patlawche11

  Read Replies (1) of 63280
 
Please, everyone take a step back from the edge, take a deep breath. From TNBC Foundation, keep them in your minds and hearts.

TNBC Foundation? @TNBCFoundation Jan 18






The FDA declined to grant accelerated approval to sacituzumab govitecan (IMMU-132, Immunomedics) for treatment of metastatic TNBC due to manufacturing issues. How do you feel that, given the government shutdown, this may delay the process even further?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News